GOT1 and metabolic dysfunction-associated steatotic liver disease: The outcome of the present study is in line with a phase IV study on liver care supplement ursodeoxycholic acid conducted in 235 patients with varied liver diseases (ALD, NAFLD, hepatitis) demonstrating a reduction in liver enzymes (ALT, AST) by 46%-55% in 12 weeks [21].